Jeffrey Bacha
Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years as a member of the executive leadership team for multiple companies. Mr. Bacha co-founded DelMar Pharmaceuticals (now, Kintara Therapeutics, Inc. NASDAQ: KTRA) with Dr. Dennis Brown and served as Chairman and CEO during the company's growth including the advancement of its lead product candidate to pivotal Phase III clinical trials and NASDAQ listing. Prior to founding DelMar, Mr. Bacha served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and Vice President, Corporate Development at Inflazyme Corp. Programs advanced by Inimex and Inflazyme have become foundational in Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (NASDAQ: AQXP). He is a member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada. Mr. Bacha currently serves as a consultant to Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA). Prior to taking on his operating roles, Mr. Bacha served Senior Manager and Director of KPMG Health Ventures, acting as an advisor to numerous public and private life sciences companies. Mr. Bacha holds an M.B.A (Hons) from the Goizueta Business School at Emory University (1995) and a degree in BioPhysics from the University of California, San Diego (1991). Mr. Bacha is the inventor or co-inventor on multiple issued U.S. patents and applications, many with foreign counterparts.
Abstracts this author is presenting: